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Abstract
Background: Hypertension is a major risk factor for cardiovascular diseases, stroke, congestive heart disease and 
renal failure. Primary hypertension is a multi-factorial complex disease and its exact etiology still remains unknown. 
In this study we aimed to compare serum amphiregulin and cerebellin-1 levels of primary hypertension patients 
with healthy subjects.
Material and methods: Forty-four hypertensive patients and 44 healthy people were included. Patients with systolic 
blood pressure measurements ≥ 140 mm Hg and diastolic blood pressure measurements ≥ 90 mm Hg were evaluated 
as hypertensive. Serum amphiregulin and cerebellin 1 levels were measured using ELISA method.
Results: Mean amphiregulin level was 32.1 (10.2–72.5) pg/mL in hypertension group and 36.9 (15.9–109.5) 
pg/mL in control group (p = 0.002). Mean cerebellin 1 levels were comparable in both groups, 82.1 (23.9–286.1) 
pg/mL in hypertensive group and 95.1 (60.2–293) pg/mL in control group (p = 0.261). Serum amphiregulin to 
predict hypertension was found to be ≤ 23 pg/mL with specificity of 97% and sensitivity of 48.5% (AUC = 0.74; 
95% CI, 0.62–0.86; p = 0.001). 
Conclusions: Hypertension is associated with lower serum amphiregulin concentrations. 
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Introduction
Hypertension is a major risk factor for cardiovascular 
diseases, stroke, congestive heart disease and renal 
failure [1]. Primary hypertension affecting approxi-
mately 95% of all cases is a multifactorial complex 
disease and its exact etiology still remains unknown. 
Genetic and environmental stimuli and their inter-
actions are thought to determine the disease [2]. It 
is estimated that over 1 billion people have been 
affected by primary hypertension [3]. Up to 54% of 
stroke and 47% of ischemic heart disease may be at-
tributed to high blood pressure worldwide [1].
Amphiregulin is a protein which acts as a ligand 
for epidermal growth factor (EGF) [4]. Epidermal 
growth factor is detectable in the serum of healthy 
individuals, as well as many other organs including: 
placenta, ovaries, testes, heart, pancreas, spleen, bone 
marrow, kidneys, lungs, colon and breasts [4, 5]. It 
has been shown that EGF can play a role in blood 
pressure regulation and deteriorate endothelial func-
tion [6, 7].
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Cerebellin is derived from precerebellin and has 
neuromodulatory functions such as maintaining of 
synaptic structures and modulating of their functions 
in the brain [8]. It has been determined that cerebel-
lin is secreted from adrenal glands, neuroendocrine 
system and pancreas [9–12]. Cerebellin has a stimu-
lating effect on the secretion of aldosterone, cortisol 
and catecholamine from the adrenal glands and this 
may contribute to an increase in blood pressure [13].
To the best of our knowledge the interplay be-
tween cerebellin, amphiregulin in primary hyperten-
sion was scarcely investigated.
Material and methods
The study followed the tenets of the Declaration 
of Helsinki and was approved by the institutional 
ethics committee (approval number: 2017/20/18) 
and informed consent was obtained from all of the 
participants. 102 patients who were admitted to the 
Emergency Department of Kahramanmaraş Sütçü 
İmam University Faculty of Medicine between Janu-
ary 2019 and December 2019 with headache and 
elevated arterial blood pressure older than 18 years 
of age were included in the study. Physical exami-
nation and arterial pressure measurements of these 
patients were performed. Arterial blood pressure 
was measured using a suitable cuff after resting the 
patients in a physically available quiet room for 5 
minutes. A special attention was paid to that the 
patients did not drink cigarettes, tea, coffee or eat 
in the last 30 minutes. The average of two or more 
office measurements obtained on two or more occa-
sions of 140/90 mm Hg and above was defined as 
hypertension [14–16]. Patients with cerebrovascular 
event, previously diagnosed hypertension patients, 
antihypertensive drug users were excluded. Patients 
who were obese or diagnosed with diabetes, Cushing 
syndrome, rheumatologic disease, chronic headache, 
migraine, intracranial mass, acute and chronic renal 
failure and active infection were also excluded from 
the study. After applying the exclusion criteria listed 
above, 55 of 102 patients were referred to the cardi-
ologist for further evaluation. Secondary hyperten-
sion (renal parenchymal disease, renovascular disease, 
primary aldosteronism, hyperthyroidism, hypothy-
roidism, hyperparathyroidism, pheochromocytoma, 
coarctation of the aorta, drug-induced hypertension 
and etc.) and white coat hypertension were ruled 
out. Echocardiographic evaluation was performed 
in all hypertensive patients. End-organ damage was 
investigated and routine laboratory values of the pa-
tients were examined. Finally forty-four newly di-
agnosed hypertension patients without end-organ 
damage were included in the study (Fig. 1). As the 
control group, 44 healthy volunteers with similar age 
and sex who presented to the outpatient clinic were 
Figure 1. Flow chart shows the patient selection process
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included in the study. Blood samples were collected 
and centrifuged at 4000 g for 10 minutes. The serum 
samples were collected and stored at –80ºC until 
required for analysis.
Transthoracic echocardiographic examinations 
were performed by experienced echocardiographers 
who were blinded about the clinical information of 
the subjects via the Vivid 7® cardiac ultrasonogra-
phy system (GE Ving-Med Ultrasound AS; Horten, 
Norway) with 2.5- to 5-MHz probes. The supine and 
left lateral positions were conducted for each patient 
with 2D, M-mode, pulsed and color flow Doppler 
echocardiography. Single lead electrocardiogram 
continuously recorded. For all measurements, the 
average of at least three cardiac cycles was evaluated. 
For the conventional Doppler echocardiographic ex-
aminations and M-mode measurements, the Euro-
pean Society of Echocardiography guideline criteria 
were used [17].
Enzyme-linked immunosorbent assay (ELISA)
Serum amphiregulin (Human Amphiregulin ELISA 
kit catalog number: 201-12-3148 Shanghai Sunred 
Biological Technology, Shanghai, China) and cer-
ebellin 1 (Human Cerebellin1 ELISA kit;  catalog 
number: 201-12-3438 Shanghai Sunred Biological 
Technology, Shanghai, China) levels were measured 
using enzyme-linked immunosorbent assay method 
according to the manufacturer’s protocol. Specimen 
absorbance values were determined on Multiskan 
FC microplate reader (Thermo Fisher Scientific) at 
a wavelength of 450 nm. Values were expressed as 
picogram/mL. The intra-assay coefficient of variance 
(CV), inter-assay CV, detection range and sensitiv-
ity of the amphiregulin kit were reported as < 10%, 
< 12%, and 4–1000 pg/mL and 3.747 pg/mL, re-
spectively. The intra-assay CV, inter-assay CV, detec-
tion range and sensitivity of the cerebellin-1 kit were 
reported as < 11%, < 12%, and 5–1500 pg/mL and 
4.385 pg/mL, respectively. 
Statistical analysis
Data management and analysis were performed us-
ing the SPSS program version 14 (SPSS Inc., Chi-
cago, IL) and a two-sided p-value ≤ 0.05 was consid-
ered statistically significant. Continuous data were 
expressed as mean ± standard deviation or median, 
and categorical data as percentages. Means were com-
pared via an independent sample t test, and if there 
was no normal distribution, via a Mann-Whitney 
U test with median. Categorical data were evaluated 
using the chi square test as appropriate. The relation-
ships between variables were assessed with Pearson 
correlation coefficient for normally distributed vari-
ables and by Spearman’s rank correlation coefficient 
for non-normally distributed variables. A receiver 
operator characteristic (ROC) curve analysis was 
performed to identify the optimal cut-off point of 
serum amphiregulin and levels for the prediction of 
hypertension. MedCalc (v. 12.7.8) was used to per-
form ROC curve analysis. The area under the curve 
(AUC) with 95% confidence interval was calculated. 
The optimal cut-off value of serum amphiregulin 
level was defined as the value associated with the 
highest sum of sensitivity and specificity-1. We used 
univariate analysis to quantify the association of vari-
ables with hypertension. The variables found to be 
statistically significant in the univariate analysis and 
other potential confounders were used in multivari-
ate logistic regression model with backward stepwise 
method in order to determine the independent prog-
nostic factors of hypertension
Results
Clinical, laboratory and echocardiographic data of 
two groups were shown in Table 1. There was no 
significant difference between groups regarding age 
and sex. Systolic pressure in hypertensive group was 
165 ± 5 mm Hg and in control group was 117 ± 
12 mm Hg (p < 0.001). Diastolic pressure in hy-
pertensive group was 98 ± 7 mm Hg and in control 
group was 77 ± 6 mm Hg (p < 0.001). There were 
significant differences between the two groups in 
terms of amphiregulin, blood urea nitrogen (BUN) 
and potassium levels. Mean amphiregulin level was 
32.1 (10.2–72.5) pg/mL in hypertension group and 
36.9 (15.9–109.5) pg/mL in control group. Amphi-
regulin level was significantly lower in hypertensive 
group (p  = 0.002). Mean cerebellin 1 levels were 
82.1 (23.9–286.1) pg/mL in hypertensive group and 
95.1 (60.2–293) pg/mL in control group. Cerebel-
lin 1 levels were similar in hypertension and control 
groups (p = 0.26). There was not any correlation 
between systolic pressure, diastolic pressure and se-
rum amphiregulin levels in hypertensive patients. 
Serum amphiregulin was correlated only with serum 
creatinine levels (r = 0.25, p = 0.03). Serum BUN 
levels were 26.8 ± 8.2 pg/mL in hypertension group 
and 16.4 ± 4.8 pg/mL in control group (p = 0.001). 
Serum potassium level was 4.6 ± 0.4 mg/dL in hyper-
tension group and 4.3 ± 0.2 mg/dL in control group 
(p = 0.001). Standard echocardiographic and other lab-
oratory parameters were similar between two groups.
Optimal cut-off levels of serum amphiregulin to 
predict hypertension was found to be ≤ 23 pg/mL 
with specificity of 97% and sensitivity of 48.5% 
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Table 1. Baseline characteristics of study patients
Parameter Hypertensive Control p value
Baseline characteristics
Age [y] 49.4 ± 11 48 ± 10 0.622
Male/female, n 21/23 22/24 0.831
SBP [mm Hg]
(mean ± SD) 165 ± 5 117 ± 12 < 0.001
DBP [mm Hg]
(mean ± SD) 98 ± 7 77 ± 6 < 0.001
Laboratory findings
Sodium [mg/dL]
(mean ± SD) 141.5 ± 3.8 140.5 ± 3.0 0.158
Potassium [mg/dL]
(mean ± SD) 4.6 ± 0.4 4.3 ± 0.2 0.001
Creatinine [mg/dL]
(mean ± SD) 0.7 ± 0.2 0.7 ± 0.1 0.101
BUN [mg/dL]
(mean ± SD) 26.8 ± 8.2 16.4 ± 4.8 < 0.001
Chloride 
[mg/dL]
(mean ± SD) 
103 ± 5 102 ± 4 0.308
Calcium [mg/dL]
(mean ± SD) 9.67 ± 0.5 10 ± 0.1 0.495
AST [U/L]
(mean ± SD) 21 ± 6.1 23.7 ± 8 0.085
ALT [U/L] 
(mean ± SD) 20 ± 9 22 ± 11 0.318
Blood glucose [mg/dL]
(mean ± SD) 102 ± 23 97 ± 13 0.359
MPV [fL]
(mean ± SD) 10.4 ± 0.8 9.9 ± 1.7 0.173
Plt [103/mm3]
(mean ± SD) 262 ± 70 240 ± 63 0.162
Hb [g/dL]
(mean ± SD) 14.2 ± 1.7 13.8 ± 1.8 0.392
HCT (%)
(mean ± SD) 41.1 ± 4.5 42.4 ± 4.3 0.212
WBC [103 mm3]
(mean ± SD) 8.0 ± 1.7 8.3 ± 2.4 0.325
RBC [106 U/L]
(mean ± SD) 5.0 ± 0.6 4.9 ± 0.3 0.452
Amphiregulin [pg/mL]
[median (IQR)] 32.1 (10.2-72.5) 36.9 (15.9-109.4) 0.002
Cerebellin [pg/mL]
[median (IQR)] 82.1 (23.9-286.1) 95.1 (60.2-293) 0.261
Echocardiographic findings
Mitral E velocity [cm/s]
(mean ± SD) 87.5 ± 9.3 91 ± 14.4 0.175
Mitral A velocity [cm/s] 
(mean ± SD) 62.4 ± 10.5 66 ± 14.5 0.185
E/A ratio 1.4 ± 0.2 1.5 ± 0.2 0.489
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[AUC = 0.74; 95% confidence interval (CI): 
0.62–0.86; p = 0.001] (Fig. 2). 
In the multiple logistic regression model, serum 
amphiregulin levels [odd ratio (OR) = 1.04, 95% CI: 
1.01–1.18, p = 0.02] and BUN (OR = 1.10, 95% 
CI: 1.02–1.18, p = 0.01) were associated with hyper-
tension after adjusting for the confounding variables, 
which were either found to be statistically significant 
in the univariate analysis and for the variables corre-
lated with serum amphiregulin levels (Tab. 2).
Discussion
To the best of our knowledge, this study is the first 
to investigate amphiregulin and cerebellin 1 in hy-
pertensive patients. It was revealed in this study that 
amphiregulin levels were low in newly diagnosed 
hypertension patients and low amphiregulin level 
was an independent predictor of newly diagnosed 
Table 2. Univariate and multivariate analyses for predicting hypertension
Variable Univariate Multivariate
p OR(95% CI) p
OR
(95% CI)
Amphiregulin 0.005 1.047 (1.014–1.081) 0.022  1.042 (1.006–1.079)
BUN < 0.001 1.121 (1.055–1.190) 0.014  1.095 (1.018–1.178)
Potassium 0.057 3.076 (0.969–9.769)
Variables which correlated with amphiregulin
Creatinine 0.099 7.827 (0.679–90.217)
All the variables from Table 1 were examined and only those significant at p < 0.05 level and correlated with amphiregulin are shown in univariate analysis. Multivariate logistic regression analysis including all the 
variables in univariate analysis with enter method. CI — confidence interval; OR — odds ratio; BUN — blood urea nitrogen
Table 1. Baseline characteristics of study patients
Parameter Hypertensive Control p value
DT [ms]
(mean ± SD) 187.7 ± 9.8 188 ± 12.7 0.689
IVRT [ms]
(mean ± SD) 87.6 ± 3 84.4 ± 14 0.107
LVEF (%)
(mean ± SD) 66 ± 5 68 ± 5 0.071
Septum thickness [mm]
(mean ± SD) 9.6 ± 1.2 9.2 ± 1.10 0.146
Posterior wall thickness [mm]
(mean ± SD) 8.8 ± 3.4 8.0 ± 1 0.133
Left atrial diameter [cm]
(mean ± SD) 34 ± 3.6 34 ± 2.2 0.88
SBP — systolic blood pressure; DBP — diastolic blood pressure; BUN — blood urea nitrogen; AST — aspartate aminotransferase; ALT — alanine aminotransferase; MPV — mean platelet volume; PLT — platelet; 
Hb — hemoglobin; HCT — hematocrit; WBC — white blood cell; RBC — red blood cell; DT — deceleration time; IVRT — isovolumetric relaxation time; LVEF — left ventricle ejection fraction; SD — standard deviation; 
IQR — interquartile range 
Figure 2. Receiver operating characteristic (ROC) curve analysis of 
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hypertension. It was found that cerebellin levels did 
not differ between the healthy group and the newly 
diagnosed hypertensive group. We also showed that 
serum urea level is high in hypertensive group and 
urea levels are associated with hypertension de novo.
Many studies have shown that EGF is associ-
ated with vascular diseases such as atherosclerosis 
and hypertension through epidermal growth factor 
receptor (EGFR). The EGFR is expressed in vas-
cular smooth muscle cells, endothelial cells, mac-
rophages and regulatory T lymphocytes, and all of 
these cells also secrete EGFR ligands [5]. Preventive 
effect of EGFR on excessive hypertrophic growth 
of cardiomyocytes and contribution of EGFR to 
the appropriate vascular wall architecture and vessel 
reactivity have been shown. With these effects EGF 
has roles supporting a physiological vascular tone 
and is also required for physiological cardiovascu-
lar tissue homeostasis [18]. Transactivation of EGF/ 
/EGFR reported to cause vasoconstriction [19]. In 
human studies plasma EGF levels were found to be 
correlated with diastolic blood pressure and carotid 
artery stiffness [20]. In an experimental study, an 
EGFR inhibitor, erlotinib failed to reduce elevated 
blood pressure in angiotensin II infused mice but 
protected animals from perivascular fibrosis [21]. 
Epidermal growth factor and its receptor are widely 
expressed in kidney and modulate glomerular hemo-
dynamics and renal metabolism. Epidermal growth 
factor and its signaling involve in cell growth, pro-
liferation, and renal electrolyte homeostasis. Activa-
tion of EGFR plays role in renal hemodynamics and 
electrolyte metabolism in kidney under physiological 
conditions [22]. Epidermal growth factor induces 
constriction of both preglomerular and postglomeru-
lar arterioles and reduces glomerular filtration and 
perfusion that may cause hypertensive effect. On the 
other hand, intravenous infusion of EGF for several 
days decreased the epithelial sodium channel activ-
ity, prevented the development of hypertension and 
attenuated renal glomerular and tubular damage in 
an experimental study [23]. Epidermal growth factor 
and EGF ligands such as amphiregulin are expected 
to be high in hypertensive patients. Contrary to our 
expectations serum amphiregulin levels were lower 
in hypertensive patients than controls in our study. 
When analyzed with the data in the literature, am-
phiregulin may have complex roles in the pathogen-
esis of hypertension. Amphiregulin may cause differ-
ent effects in pathological and physiological processes 
as EGF and EGFR discussed in the above articles. 
Rather than activator roles amphiregulin may have 
regulatory functions in blood pressure. The patients 
in our study group were hypertensive and were not 
taking any antihypertensive drugs. Amphiregulin 
levels in these patients may have been found to be 
low in order to reduce vasoconstriction in vascu-
lar smooth muscle due to the body’s compensation 
mechanisms. On the other hand, the vasoconstrictor 
effects of amphiregulin on glomerular precapillary 
and post-capillary arterioles may have been tried to 
be compensated by reducing the release of amphi-
regulin in hypertensive patients. Perhaps the primary 
cause of the hypertension in these patients may be 
due to a mutation in the amphiregulin gene or the 
amount of amphiregulin may not be released enough 
to balance the vascular tone. More comprehensive 
and large-scale studies are needed to clarify the exact 
mechanism.
The early stage of primary hypertensive kidney 
involvement is characterized by afferent arteriolar 
vasoconstriction. Thus, renal blood flow and effective 
renal plasma flow (ERPF) are reduced, glomerular 
filtration rate (GFR) is maintained within relatively 
normal limits and filtration fraction (GFR/ERPF) 
increases [24, 25]. Microproteinuria occurs due to 
the increase in the filtration fraction. Microprotein-
uria is responsible for the onset and progression of 
tubulointerstitial injury [24, 26]. A decrease in renal 
blood flow reduces tubular urea secretion. Excessive 
absorption of sodium and water from the proxi-
mal tubules increases post-secretory urea absorption. 
Therefore, an increase in serum urea level may occur 
[27]. Since these hemodynamic events are poten-
tially reversible, it is very important to detect kidney 
involvement at an early stage. We revealed in this 
study that the blood urea levels of newly diagnosed 
hypertension patients were high. In addition, high 
blood urea values  were an independent variable for 
hypertension. Because blood urea levels are affected 
by many pathologies, it may not be appropriate to 
use this parameter in the first diagnosis of primary 
hypertension.
Investigations about the effects of cerebellin on 
circulation are very limited. Rucinski et al. dem-
onstrated that cerebellin-derived peptides have ad-
renocorticotropic hormone (ACTH)-like effects on 
corticosterone output and proliferative activity of 
cultured rat adrenocortical cells [28]. Previous stud-
ies showed that cerebellin is a potent stimulator of 
direct norepinephrine release by rat adrenal medulla 
and enhances adrenocortical steroid secretion. Adre-
nocortical secretagogue effect of cerebellin is medi-
ated by locally released catecholamines that act on 
the cortex in a paracrine manner [29, 30]. Gauli et 
al. reported that autonomous aldosterone secretion 
is more prevalent among patients with primary hy-
pertension and significantly correlated with systolic 
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and diastolic arterial blood pressure [31]. Cerebellin 
increases norepinephrine release from the adrenal 
medulla. Previous studies have shown a relation-
ship between hypertension and sympathetic system 
activation. Before starting the study we hypothesized 
that the increase of sympathetic activity in hyperten-
sive patients may be caused by high cerebellin levels. 
However, cerebellin-1 levels were lower in hyper-
tensive patients than in the control group, without 
statistical significance. 
In another study, we compared the serum amphi-
regulin and cerebellin 1 levels of severe preeclampsia 
patients with healthy pregnant women and healthy 
normotensive nonpregnant women control subjects. 
We found significantly decreased serum amphiregu-
lin and cerebellin 1 levels in severe preeclampsia pa-
tients compared with healthy pregnant women and 
controls [32]. Serum amphiregulin was also lower in 
patients with hypertension in current study. Serum 
cerebellin levels were similar in hypertensive and 
healthy individuals, contrary to our expectations. 
As it is known, compared to primary hypertension, 
preeclampsia is a more acute and rapidly progress-
ing pathology. Hypothetically rapid and appropri-
ate cerebellin secretion response may not occur in 
preeclampsia patients compared to those of primary 
hypertension patients.
Our study has some limitations. If we studied 
aforementioned molecules such as norepinephrine 
and aldosterone that contributes to the pathogenesis 
of hypertension in combination with amphiregu-
lin and cerebellin 1, we would have achieved more 
precise results. According to the results of our study, 
serum amphiregulin indicate the presence of hyper-
tension rather than its severity.
In conclusion, serum amphiregulin appears to be 
lower in primary hypertension patients when compared 
to normotensives. Low amphiregulin (≤ 23 pg/mL) 
can be used to support the diagnosis of primary 
hypertension. 
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